Results 61 to 70 of about 49,177 (212)
Digital and Biomarker‐Based Monitoring for Schizophrenia‐Treatment Adherence
Neuropsychopharmacology Reports, Volume 46, Issue 3, September 2026.Monitoring technologies integrated with artificial intelligence can enable personalized care, improved adherence, and reduced relapses among psychotic patients. ABSTRACT Background Nonadherence to antipsychotics affects nearly half of patients with schizophrenia, leading to rehospitalization, suicidality, and reduced quality of life.
Samuel Inshutiyimana +5 more
wiley +1 more source
Xanomeline and Trospium Chloride: Mechanism of Action, Clinical, and Translational Science
Clinical and Translational Science, Volume 19, Issue 9, September 2026.ABSTRACT Xanomeline‐trospium chloride (Cobenfy, formerly KarXT) is a first‐in‐class, oral central M1/M4 muscarinic receptor agonist approved for the treatment of schizophrenia in adults. Cobenfy represents a paradigm shift by avoiding direct dopamine D2 receptor blockade and thus significantly reduces the burden of metabolic, extrapyramidal, and ...
Samantha Avila, Ingrid L. Chen
wiley +1 more source
Tardive Dyskinesia and Perceptual Dysfunction
, 1981 There is equivocal evidence for a relationship between neuroleptic-induced tardive dyskinesia and central nervous system (CNS) dysfunction. Using the Bender-Gestalt test as the dependent measure, we hypothesized that a group of chronic schizophrenic ...
Dilip V. Jeste +2 more
core +1 more source
Early Intervention in Psychiatry, Volume 20, Issue 9, September 2026.ABSTRACT Introduction While early intervention services (EIS) have demonstrated short‐term benefits, the long‐term maintenance of these gains remains uncertain. Individuals with first‐episode psychosis exhibit significant variability in their course of recovery.
Olivier Percie du Sert +9 more
wiley +1 more source
, 2019 Tardive dyskinesia is now widely recognised as a neurological disorder associated with the administration of antipsychotic drugs. Prevalence is higher among the elderly.
Blowers, A. J., Blowers, Anthony John
core
Journal of Applied Research in Intellectual Disabilities, Volume 39, Issue 5, September 2026.ABSTRACT Background Assessing movement disorders—side effects of antipsychotics—can be challenging in people with intellectual disabilities. This systematic literature review aims to provide a comprehensive overview of the psychometric properties of instruments used to assess movement disorders in people with intellectual disabilities using ...
Maria Louise Dieudonnée Hoekstra‐van Duijn +4 more
wiley +1 more source
Tetrabenazine for the Treatment of Tardive Dyskinesia
, 2011 Objective: To evaluate the safety and effectiveness of tetrabenazine for the treatment of tardive dyskinesia. Data Sources: Literature was accessed through MEDLINE (1966-September 2010) and The Cochrane Library using the terms tetrabenazine, tardive ...
Jonathan G Leung, Ericka L Breden
core +1 more source
Tardive dyskinesia and deficit schizophrenia
, 2011 IntroductionDespite comparable antipsychotic exposure, some patients experience involuntary movements yet others do not. Negative symptoms have been associated with tardive dyskinesia, but it is not certain that this is an association with primary ...
R. McCreadie +3 more
core +2 more sources
Neuropsychiatric Disease and Treatment, 2014 Norio Yasui-Furukori,1 Atsuhiro Kikuchi,1 Hiroshi Katagai,1,2 Sunao Kaneko11Department of Neuropsychiatry, Hirosaki University School of Medicine, 2Department of Neuropsychiatry, Hirosaki-Aiseikai Hospital, Hirosaki, JapanBackground: Tardive dystonia and
Yasui-Furukori N +3 more
doaj
Drug-induced tardive dyskinesia
Неврология, нейропсихиатрия, психосоматика, 2020 Tardive dyskinesia (TD) is a type caused by the use of different medications. The pathogenesis of TD is associated with dopamine receptor blockade, gamma-aminobutyric acid depletion, cholinergic deficiency, oxidative stress, impaired synaptic plasticity,
T. M. Ostroumova +3 more
doaj +1 more source